Search Results - "Li, Yvonne Y"

Mechanisms and therapeutic implications of hypermutation in gliomas by Touat, Mehdi, Li, Yvonne Y., Boynton, Adam N., Spurr, Liam F., Iorgulescu, J. Bryan, Bohrson, Craig L., Cortes-Ciriano, Isidro, Birzu, Cristina, Geduldig, Jack E., Pelton, Kristine, Lim-Fat, Mary Jane, Pal, Sangita, Ferrer-Luna, Ruben, Ramkissoon, Shakti H., Dubois, Frank, Bellamy, Charlotte, Currimjee, Naomi, Bonardi, Juliana, Qian, Kenin, Ho, Patricia, Malinowski, Seth, Taquet, Leon, Jones, Robert E., Shetty, Aniket, Chow, Kin-Hoe, Sharaf, Radwa, Pavlick, Dean, Albacker, Lee A., Younan, Nadia, Baldini, Capucine, Verreault, Maïté, Giry, Marine, Guillerm, Erell, Ammari, Samy, Beuvon, Frédéric, Mokhtari, Karima, Alentorn, Agusti, Dehais, Caroline, Houillier, Caroline, Laigle-Donadey, Florence, Psimaras, Dimitri, Lee, Eudocia Q., Nayak, Lakshmi, McFaline-Figueroa, J. Ricardo, Carpentier, Alexandre, Cornu, Philippe, Capelle, Laurent, Mathon, Bertrand, Barnholtz-Sloan, Jill S., Chakravarti, Arnab, Bi, Wenya Linda, Chiocca, E. Antonio, Fehnel, Katie Pricola, Alexandrescu, Sanda, Chi, Susan N., Haas-Kogan, Daphne, Batchelor, Tracy T., Frampton, Garrett M., Alexander, Brian M., Huang, Raymond Y., Ligon, Azra H., Coulet, Florence, Delattre, Jean-Yves, Hoang-Xuan, Khê, Meredith, David M., Santagata, Sandro, Duval, Alex, Sanson, Marc, Cherniack, Andrew D., Wen, Patrick Y., Reardon, David A., Marabelle, Aurélien, Park, Peter J., Idbaih, Ahmed, Beroukhim, Rameen, Bandopadhayay, Pratiti, Bielle, Franck, Ligon, Keith L.

“…A high tumour mutational burden (hypermutation) is observed in some gliomas 1 – 5 ; however, the mechanisms by which hypermutation develops and whether it…”
Get full text

Genomic analysis of metastatic cutaneous squamous cell carcinoma by Li, Yvonne Y, Hanna, Glenn J, Laga, Alvaro C, Haddad, Robert I, Lorch, Jochen H, Hammerman, Peter S

“…A rare 5% of cutaneous squamous cell carcinomas (cSCC) metastasize, lack FDA-approved therapies, and carry a poor prognosis. Our aim was to identify recurrent…”
Get full text

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints by Koyama, Shohei, Akbay, Esra A., Li, Yvonne Y., Herter-Sprie, Grit S., Buczkowski, Kevin A., Richards, William G., Gandhi, Leena, Redig, Amanda J., Rodig, Scott J., Asahina, Hajime, Jones, Robert E., Kulkarni, Meghana M., Kuraguchi, Mari, Palakurthi, Sangeetha, Fecci, Peter E., Johnson, Bruce E., Janne, Pasi A., Engelman, Jeffrey A., Gangadharan, Sidharta P., Costa, Daniel B., Freeman, Gordon J., Bueno, Raphael, Hodi, F. Stephen, Dranoff, Glenn, Wong, Kwok-Kin, Hammerman, Peter S.

“…Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in lung…”
Get full text

Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer by Ricciuti, Biagio, Recondo, Gonzalo, Spurr, Liam F, Li, Yvonne Y, Lamberti, Giuseppe, Venkatraman, Deepti, Umeton, Renato, Cherniack, Andrew D, Nishino, Mizuki, Sholl, Lynette M, Shapiro, Geoffrey I, Awad, Mark M, Cheng, Michael L

“…DNA damage response and repair (DDR) gene alterations are associated with increased tumor-infiltrating lymphocytes, higher genomic instability, and higher…”
Get full text

Drug repositioning for personalized medicine by Li, Yvonne Y, Jones, Steven Jm

“…Human diseases can be caused by complex mechanisms involving aberrations in numerous proteins and pathways. With recent advances in genomics, elucidating the…”
Get full text

A computational approach to finding novel targets for existing drugs by Li, Yvonne Y, An, Jianghong, Jones, Steven J M

“…Repositioning existing drugs for new therapeutic uses is an efficient approach to drug discovery. We have developed a computational drug repositioning pipeline…”
Get full text

Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity by Miret, Juan J, Kirschmeier, Paul, Koyama, Shohei, Zhu, Mingrui, Li, Yvonne Y, Naito, Yujiro, Wu, Min, Malladi, Venkat S, Huang, Wei, Walker, William, Palakurthi, Sangeetha, Dranoff, Glenn, Hammerman, Peter S, Pecot, Chad V, Wong, Kwok-Kin, Akbay, Esra A

“…Tumor orchestrated metabolic changes in the microenvironment limit generation of anti-tumor immune responses. Availability of arginine, a semi-essential amino…”
Get full text

Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer by Zhang, Haikuo, Qi, Jun, Reyes, Jaime M, Li, Lewyn, Rao, Prakash K, Li, Fugen, Lin, Charles Y, Perry, Jennifer A, Lawlor, Matthew A, Federation, Alexander, De Raedt, Thomas, Li, Yvonne Y, Liu, Yan, Duarte, Melissa A, Zhang, Yanxi, Herter-Sprie, Grit S, Kikuchi, Eiki, Carretero, Julian, Perou, Charles M, Reibel, Jacob B, Paulk, Joshiawa, Bronson, Roderick T, Watanabe, Hideo, Brainson, Christine Fillmore, Kim, Carla F, Hammerman, Peter S, Brown, Myles, Cichowski, Karen, Long, Henry, Bradner, James E, Wong, Kwok-Kin

“…As a master regulator of chromatin function, the lysine methyltransferase EZH2 orchestrates transcriptional silencing of developmental gene networks…”
Get more information

Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants by Hayes, Tikvah K., Aquilanti, Elisa, Persky, Nicole S., Yang, Xiaoping, Kim, Erica E., Brenan, Lisa, Goodale, Amy B., Alan, Douglas, Sharpe, Ted, Shue, Robert E., Westlake, Lindsay, Golomb, Lior, Silverman, Brianna R., Morris, Myshal D., Fisher, Ty Running, Beyene, Eden, Li, Yvonne Y., Cherniack, Andrew D., Piccioni, Federica, Hicks, J. Kevin, Chi, Andrew S., Cahill, Daniel P., Dietrich, Jorg, Batchelor, Tracy T., Root, David E., Johannessen, Cory M., Meyerson, Matthew

“…The epidermal growth factor receptor, EGFR, is frequently activated in lung cancer and glioblastoma by genomic alterations including missense mutations. The…”
Get full text

Loss of heterozygosity does not occur in BRCA1/2 mutant pediatric solid and central nervous system tumors by Groves, Andrew, Ward, Abigail, Li, Yvonne Y, Lazo de la Vega, Lorena, Nag, Anwesha, Forrest, Suzanne J, Gupta, Hersh V, Thorner, Aaron R, Meyerson, Matthew, Kamihara, Junne, Cherniack, Andrew D, Janeway, Katherine A

“…Utilization of tumor-only sequencing has expanded in pediatric cancer patients, which can lead to identification of pathogenic variants in genes that may be…”
Get full text

Author Correction: Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants by Hayes, Tikvah K., Aquilanti, Elisa, Persky, Nicole S., Yang, Xiaoping, Kim, Erica E., Brenan, Lisa, Goodale, Amy B., Alan, Douglas, Sharpe, Ted, Shue, Robert E., Westlake, Lindsay, Golomb, Lior, Silverman, Brianna R., Morris, Myshal D., Fisher, Ty Running, Beyene, Eden, Li, Yvonne Y., Cherniack, Andrew D., Piccioni, Federica, Hicks, J. Kevin, Chi, Andrew S., Cahill, Daniel P., Dietrich, Jorg, Batchelor, Tracy T., Root, David E., Johannessen, Cory M., Meyerson, Matthew

Get full text

Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer by Herter-Sprie, Grit S, Koyama, Shohei, Korideck, Houari, Hai, Josephine, Deng, Jiehui, Li, Yvonne Y, Buczkowski, Kevin A, Grant, Aaron K, Ullas, Soumya, Rhee, Kevin, Cavanaugh, Jillian D, Neupane, Neermala Poudel, Christensen, Camilla L, Herter, Jan M, Makrigiorgos, G Mike, Hodi, F Stephen, Freeman, Gordon J, Dranoff, Glenn, Hammerman, Peter S, Kimmelman, Alec C, Wong, Kwok-Kin

“…Radiation therapy (RT), a critical modality in the treatment of lung cancer, induces direct tumor cell death and augments tumor-specific immunity. However,…”
Get full text

Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6 by Choudhury, Atish D, Schinzel, Anna C, Cotter, Maura B, Lis, Rosina T, Labella, Katherine, Lock, Ying Jie, Izzo, Francesca, Guney, Isil, Bowden, Michaela, Li, Yvonne Y, Patel, Jinal, Hartman, Emily, Carr, Steven A, Schenone, Monica, Jaffe, Jacob D, Kantoff, Philip W, Hammerman, Peter S, Hahn, William C

“…In prostate cancer, the development of castration resistance is pivotal in progression to aggressive disease. However, understanding of the pathways involved…”
Get full text

Genomic landscape of human papillomavirus-associated cancers by Rusan, Maria, Li, Yvonne Y, Hammerman, Peter S

“…Recent next-generation sequencing studies have generated a comprehensive overview of the genomic landscape of human papillomavirus (HPV)-associated cancers…”
Get full text

Improving the specificity of high-throughput ortholog prediction by Fulton, Debra L, Li, Yvonne Y, Laird, Matthew R, Horsman, Benjamin G S, Roche, Fiona M, Brinkman, Fiona S L

“…Orthologs (genes that have diverged after a speciation event) tend to have similar function, and so their prediction has become an important component of…”
Get full text

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status by Ricciuti, Biagio, Arbour, Kathryn C, Lin, Jessica J, Vajdi, Amir, Vokes, Natalie, Hong, Lingzhi, Zhang, Jianjun, Tolstorukov, Michael Y, Li, Yvonne Y, Spurr, Liam F, Cherniack, Andrew D, Recondo, Gonzalo, Lamberti, Giuseppe, Wang, Xinan, Venkatraman, Deepti, Alessi, Joao V, Vaz, Victor R, Rizvi, Hira, Egger, Jacklynn, Plodkowski, Andrew J, Khosrowjerdi, Sara, Digumarthy, Subba, Park, Hyesun, Vaz, Nuno, Nishino, Mizuki, Sholl, Lynette M, Barbie, David, Altan, Mehmet, Heymach, John V, Skoulidis, Ferdinandos, Gainor, Justin F, Hellmann, Matthew D, Awad, Mark M

“…STK11 and KEAP1 mutations (STK11 mutant [STK11 ] and KEAP1 ) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11 has been…”
Get more information

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC by Recondo, Gonzalo, Bahcall, Magda, Spurr, Liam F, Che, Jianwei, Ricciuti, Biagio, Leonardi, Giulia C, Lo, Ying-Chun, Li, Yvonne Y, Lamberti, Giuseppe, Nguyen, Tom, Milan, Marina S D, Venkatraman, Deepti, Umeton, Renato, Paweletz, Cloud P, Albayrak, Adem, Cherniack, Andrew D, Price, Kristin S, Fairclough, Stephen R, Nishino, Mizuki, Sholl, Lynette M, Oxnard, Geoffrey R, Jänne, Pasi A, Awad, Mark M

“…Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKI) are poorly understood. We aimed to characterize the genomic mechanisms of…”
Get full text

SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition by Alessi, Joao V, Ricciuti, Biagio, Spurr, Liam F, Gupta, Hersh, Li, Yvonne Y, Glass, Carolyn, Nishino, Mizuki, Cherniack, Andrew D, Lindsay, James, Sharma, Bijaya, Felt, Kristen D, Rodig, Scott J, Cheng, Michael L, Sholl, Lynette M, Awad, Mark M

“…The SWItch/Sucrose Nonfermentable (SWI/SNF) chromatin remodeling complex acts as a regulatory component of transcription, and inactivating mutations (muts)…”
Get more information

PEComa With MITF Overexpression: Clinicopathologic and Molecular Analysis of a Series of 36 Cases by Hanna, John, Russell-Goldman, Eleanor, Baranov, Esther, Pissaloux, Daniel, Li, Yvonne Y, Tirode, Franck, de la Fouchardiere, Arnaud, Fletcher, Christopher D M

“…Perivascular epithelioid cell neoplasms (PEComas) are tumors of uncertain cell lineage that occur across a wide age range, at a variety of anatomic sites, and…”
Get full text

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment by Koyama, Shohei, Akbay, Esra A, Li, Yvonne Y, Aref, Amir R, Skoulidis, Ferdinandos, Herter-Sprie, Grit S, Buczkowski, Kevin A, Liu, Yan, Awad, Mark M, Denning, Warren L, Diao, Lixia, Wang, Jing, Parra-Cuentas, Edwin R, Wistuba, Ignacio I, Soucheray, Margaret, Thai, Tran, Asahina, Hajime, Kitajima, Shunsuke, Altabef, Abigail, Cavanaugh, Jillian D, Rhee, Kevin, Gao, Peng, Zhang, Haikuo, Fecci, Peter E, Shimamura, Takeshi, Hellmann, Matthew D, Heymach, John V, Hodi, F Stephen, Freeman, Gordon J, Barbie, David A, Dranoff, Glenn, Hammerman, Peter S, Wong, Kwok-Kin

“…STK11/LKB1 is among the most commonly inactivated tumor suppressors in non-small cell lung cancer (NSCLC), especially in tumors harboring KRAS mutations. Many…”
Get full text